Male Infertility (asthenozoospermia) Cell Models for Research

Male infertility affects approximately 7% of men worldwide, with asthenozoospermia (reduced sperm motility) being a leading cause. According to the World Health Organization (WHO), infertility affects 15% of couples globally, with male factors contributing to about 50% of cases. Asthenozoospermia is diagnosed when less than 32% of sperm exhibit progressive motility (WHO 5th edition criteria). The condition has significant psychological and economic impacts, yet its molecular basis remains poorly understood, highlighting the need for robust research models.

Asthenozoospermia is ideal for mechanistic studies due to its defined clinical phenotype and the availability of patient-derived samples. However, primary sperm cells are limited in availability and difficult to culture. Gene-edited cell models, such as immortalized spermatogonial stem cells or testicular cell lines, offer a renewable and genetically manipulable alternative. Key research questions include identifying genetic variants that affect sperm motility, understanding flagellar assembly, and developing targeted therapies. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project, provide expression data for genes implicated in spermatogenesis.

Sperm motility is driven by the axoneme, a microtubule-based structure. Key pathways include:

• • Calcium Signaling: Calcium influx through CatSper channels (CATSPER1-4) is essential for hyperactivation and chemotaxis. Disruption leads to asthenozoospermia.
• • cAMP/PKA Pathway: Cyclic AMP activates protein kinase A (PKA), which phosphorylates proteins involved in flagellar movement. Defects in this pathway impair motility.
• • Mitochondrial Function: ATP production via oxidative phosphorylation is critical for flagellar beating. Mitochondrial DNA mutations or dysfunction can cause asthenozoospermia.
• • Flagellar Assembly: Intraflagellar transport (IFT) and dynein arm components (e.g., DNAH1, DNAH5) are essential for axoneme structure. Mutations in these genes cause primary ciliary dyskinesia and asthenozoospermia.

Data compiled from ClinVar and COSMIC databases.

Key signaling networks deregulated in asthenozoospermia include:

• • CatSper Signaling: CATSPER channels are voltage-gated calcium channels. Mutations in any of the four pore-forming subunits (CATSPER1-4) or auxiliary subunits (CATSPERB, CATSPERD, CATSPERG) lead to loss of calcium influx and impaired hyperactivation.
• • cAMP/PKA Pathway: Adenylyl cyclase (ADCY10) produces cAMP, which activates PKA. PKA phosphorylates targets like AKAP4, which anchors regulatory subunits. Disruption of this pathway reduces flagellar beat frequency.
• • Mitochondrial Apoptosis Pathway: Oxidative stress can trigger mitochondrial permeability transition, releasing cytochrome c and activating caspases, leading to sperm cell death and reduced motility.
• • PI3K/AKT Pathway: This pathway regulates cell survival and motility. Aberrant activation may lead to abnormal sperm function.

Organoids derived from testicular tissue can recapitulate spermatogenesis in vitro, providing a more physiologically relevant model. They can be gene-edited to study specific mutations.

Animal models for asthenozoospermia include:

• • Knockout mice: Targeted disruption of genes like Catsper1, Dnah1, and Akap4 results in male infertility with reduced sperm motility.
• • Transgenic mice: Overexpression of mutant forms of genes can model dominant negative effects.
• • Chemical-induced models: Administration of agents like busulfan or cyclophosphamide can induce testicular damage and asthenozoospermia.
• • Patient-derived xenografts (PDX): Testicular tissue from patients can be xenografted into immunodeficient mice to study spermatogenesis, though this is less common.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For asthenozoospermia research, commercially available gene-edited cell models include:

• • CATSPER1 knockout cell lines: Generated in GC-2 or TCam-2 cells to study calcium signaling defects.
• • DNAH1 mutant knock-in lines: Introduce specific point mutations to model dynein arm defects.
• • AKAP4 knockout lines: Used to investigate fibrous sheath integrity.

These sequence-verified models allow researchers to study the functional consequences of specific mutations in a controlled background, accelerating drug discovery and target validation. They are available from commercial sources and can be custom-generated.

Gene-edited cell lines are essential for validating the role of candidate genes in sperm motility. For example, knocking out CATSPER1 in a spermatocyte cell line leads to reduced calcium influx and decreased motility, confirming its functional importance. Similarly, introducing a DNAH1 mutation can recapitulate axonemal defects observed in patients. These models enable high-throughput screening of genetic variants and identification of novel therapeutic targets.

Isogenic pairs (wild-type vs. knockout) are powerful tools for drug screening. For instance, a CATSPER1 knockout line can be used to screen for compounds that rescue calcium influx or bypass the defect. Additionally, gene-edited lines can be used to test the efficacy of drugs that modulate cAMP/PKA signaling or mitochondrial function. Resistance mechanisms to existing treatments can also be studied by generating resistant cell lines through CRISPR-mediated mutagenesis.

CRISPR-based synthetic lethality screens can identify genes that are essential for cell survival in the context of specific mutations. For example, in a DNAH1 mutant background, screening for genes whose knockdown causes cell death may reveal novel therapeutic targets. Gene-edited cell lines also enable the identification of biomarkers for asthenozoospermia by comparing protein and transcript profiles between wild-type and mutant cells.